ABSTRACT
OBJECTIVE： To investigate the correlation of 5-hydroxytryptamine 2A receptor （5-HT2AR） rs6313 gene polymorphism with pain occurrence and opioid requirements in patients with lung cancer. METHODS： Totally 332 patients with lung cancer were selected from the Affiliated Hospital of Xuzhou Medical University during Dec. 2017-Jun. 2018 as lung cancer group. They were divided into pain group （177 cases） and painless group （155 cases） according to whether pain occurred. Totally 116 healthy persons who underwent physical examination in same period were selected as control group. The genotype of rs6313 locus of 5-HT2AR gene was detected by PCR-RFLP. The distribution of genotype was compared by χ2-test. The correlation of genotype with pain occurrence and degree， opioids requirements were investigated by Binary Logistic regression analysis， χ2-test and Kruskal-Wallis test. RESULTS： CC， CT， TT genotypes were detected in rs6313 locus of 5-HT2AR gene. The frequency of above genotypes were 20.7％， 47.4％， 31.9％， 20.6％， 50.3％， 29.0％ as well as 16.4％， 50.8％， 32.8％， respectively in control group， painless group and pain group. Their frequencies and allele frequencies were in line with Hardy-Weinberg balance （P＞0.05）. There was no statistical significance in genotype and allele frequencies between lung cancer group and control group （P＞0.05）. TNM staging （Ⅲ-Ⅳ stage） was associated with pain in lung cancer patients [OR＝3.661， 95％CI （1.972，6.797）， P＜0.001]. Gender， age， height， body weight， pathological typing and rs6313 locus genotype had no correlation with pain （P＞0.05）. The genotype of this locus was not related to the degree of pain and the requirements for opioids in patients with lung cancer （P＞0.05）. CONCLUSIONS： The polymorphism of 5-HT2AR gene rs6313 locus is no related to pain occurrence and opioid requirements in patients with lung cancer. Its polymorphism may not be the main cause of individual pain differences in lung cancer patients.
ABSTRACT
Background 5-hydroxytryptamine 2A receptor (5-HT2A) gene has been regarded as a candidate gene for susceptibility to schizophrenia. In particular, the 5-HT2A receptor has received much attention because it demonstrates to be an important site of action of atypical antipsychotic agents to alleviate negative symptoms. The current study investigated whether the 5-hydroxytryptamine 2A receptor (5-HT2A) gene T102C polymorphism was associated with treatment response to risperidone in the first episode Chinese patients with schizophrenia.Methods 201 first episode Chinese Han patients with schizophrenia were given risperidone for up to 56 days.Genotyping of 5-HT2A gene T102C polymorphism were performed by using PCR-RFLP. The Positive and Negative Symptom Scale (PANSS) was used for the evaluation of the severity of psychotic symptoms before and after 8 weeks treatment with risperidone.Results 5-HT2A receptor 102 -T/T genotype was significantly associated with both the PANSS total and negative syndrome subscale scores before treatment, and with the reduction rates in both the PANSS total and negative syndrome subscale scores after eight weeks risperidone treatment.Conclusions The results suggest that 5-HT2A T102C A/A1 genotype subgroup influences individual response to risperidone in first-episode Chinese patients with schizophrenia.